Nippon Shinyaku CoTSE:4516 -0.25%90 EBITDA Margin % is 11.51% as of Mar. 2026, which is 54% below its 10-year median of 25.04. GuruFocus rates TSE:4516 with a GF Score™ of 90/100 and a GF Value™ of 円4,785.64 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Nippon Shinyaku Co ranks better than 78.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nippon Shinyaku Co's EBITDA for the
three
months ended in Mar. 2026 was 円5,021 Mil. Nippon Shinyaku Co's Revenue for the
three
months ended in Mar. 2026 was 円43,636 Mil. Therefore, Nippon Shinyaku Co's EBITDA margin for the quarter that ended in Mar. 2026 was 11.51%.
Nippon Shinyaku Co (TSE:4516) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nippon Shinyaku Co EBITDA Margin % Related Terms
Nippon Shinyaku Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nippon Shinyaku Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Shinyaku Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Shinyaku Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Shinyaku Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nippon Shinyaku Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Shinyaku Co (TSE:4516) has a EBITDA Margin % of 11.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nippon Shinyaku Co and its competitors. This is 54% below median its historical median of 25.04. Over the past decade, Nippon Shinyaku Co's EBITDA Margin % has ranged from 18.35 to 27.65. According to the industry distribution chart, Nippon Shinyaku Co ranks #202 out of 955 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Nippon Shinyaku Co's EBITDA Margin % too high?
Nippon Shinyaku Co's current EBITDA Margin % of 11.51% is 54% below median its 10-year median of 25.04. Over the past 10 years, this metric has ranged from a low of 18.35 to a high of 27.65. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Nippon Shinyaku Co's value of 11.51% is 7.5% below this industry median. Based on the distribution chart, Nippon Shinyaku Co ranks #202 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nippon Shinyaku Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nippon Shinyaku Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Shinyaku Co ranks #202 out of 955 companies for EBITDA Margin %. This places Nippon Shinyaku Co in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Nippon Shinyaku Co's value of 11.51% is 7.5% below this benchmark. Historically, Nippon Shinyaku Co's own EBITDA Margin % has ranged from 18.35 to 27.65 over the past decade. While the company's 10-year median is 25.04 vs. the industry median of 12.44, Nippon Shinyaku Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Shinyaku Co's current EBITDA Margin % of 11.51% is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nippon Shinyaku Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Shinyaku Co's current EBITDA Margin % is 11.51%, which is 54% below median its own 10-year median of 25.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Shinyaku Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Shinyaku Co (TSE:4516) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,785.64, compared to a current price of 円4,037.00 — trading 15.6% below its estimated fair value. The current EBITDA Margin % is 11.51%, which is 54% below median its 10-year median of 25.04 and 7.5% below the Drug Manufacturers industry median of 12.44. Nippon Shinyaku Co's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nippon Shinyaku Co (TSE:4516), the current EBITDA Margin % is 11.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Shinyaku Co (TSE:4516) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Shinyaku Co stock appears to be undervalued.
The current stock price of 円4,037.00 is trading 15.6% below its estimated GF Value™ of 円4,785.64.
GuruFocus considers Nippon Shinyaku Co to be Modestly Undervalued.
Key valuation signals for TSE:4516:
EBITDA Margin %: 11.51% (54% below median its 10-year median of 25.04)
GF Value™: 円4,785.64 vs. price of 円4,037.00 (15.6% below fair value)
Industry Position: 7.5% below the Drug Manufacturers median (#202 of 955)
No single metric tells the full story. See the TSE:4516 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
90GF Score
Get the complete analysis for TSE:4516
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4516 has been successfully added to your 
